Noviets Pharma v Novartis: Genericness Plea Fails on Estoppel

• Novartis AG secured an interim injunction against Noviets Pharma in a trademark dispute over pharmaceutical marks.
• Noviets Pharma's appeal against the interim injunction was dismissed by the Division Bench.
• Noviets argued that the prefix "NOV" in their mark was generic and common in the pharmaceutical trade.
• The Single Judge rejected Noviets's genericness plea, applying the principle of estoppel due to Noviets's own prior application to register "NOVIETS."
• The underlying trademark infringement suit between Noviets Pharma and Novartis AG remains pending trial.

The court determined that Noviets Pharma, having previously sought registration for its own mark "NOVIETS," was legally barred from contending that the "NOV" prefix was generic or common to the trade.

A significant trademark dispute in the Indian pharmaceutical sector, Noviets Pharma v. Novartis AG, has brought to light critical aspects of genericness pleas and the principle of estoppel. The case involves two pharmaceutical entities: Novartis AG, which has held a registered trademark for "NOVARTIS" since 1996, and Noviets Pharma, a group of interconnected companies operating in the pharmaceutical and veterinary product markets, which began using the mark "NOVIETS" around 2017-2018.

The conflict escalated when Novartis successfully secured an interim injunction against Noviets from a Single Judge in a suit identified as CS(COMM) 218/2024. Following this, Noviets Pharma lodged an appeal against the interim order. However, the Division Bench subsequently dismissed Noviets's appeal, affirming the Single Judge's discretionary decision and finding no grounds for perversity under the established Wander standard. The primary infringement suit between the parties is still awaiting trial before the Single Judge.

Central to Noviets Pharma's defense was a genericness plea, asserting that the prefix "NOV" within their mark is common to the pharmaceutical trade, being derived from terms like "Nova" or "New." This argument aimed to undermine the distinctiveness of the "NOV" element, which is also present in Novartis's mark. However, the Single Judge found this defense to be fundamentally flawed due to Noviets's own prior actions.

The court determined that Noviets Pharma, having previously sought registration for its own mark "NOVIETS," was legally barred from contending that the "NOV" prefix was generic or common to the trade. This ruling invoked the legal principle that a party cannot 'approbate and reprobate,' meaning one cannot take inconsistent positions in legal proceedings. Consequently, the Single Judge concluded that Noviets's own application for trademark registration was fatal to their genericness argument, effectively creating an estoppel against them.

The decision in Noviets v Novartis regarding the genericness plea underscores a crucial point for trademark litigation and strategy in India. It highlights how a party's own historical actions, particularly the act of applying for a trademark registration, can be used to estop them from later arguing that a component of that very mark is generic. This legal stance means that a defendant's ability to claim genericness as a defense can be severely compromised if they have previously sought to assert proprietary rights over the disputed element.

This case serves as a significant reminder for legal practitioners advising on trademark strategy in India. It emphasizes the need for careful consideration of all potential implications when seeking trademark registrations, as such actions can inadvertently create an estoppel, thereby limiting future defensive arguments in infringement suits. The ongoing nature of the underlying suit means that while the interim injunction stands and the genericness plea has been rejected on estoppel grounds, the full merits of the case are yet to be decided.

Lawyers advising on trademark strategy or litigation in India must be aware that a client's own prior actions, such as seeking registration for a mark, can be used to estop them from arguing that a component of that mark is generic, thereby undermining a key defense in infringement suits.

Source: Original reporting via legal analysis of court proceedings